Save the date for MVEC’s Immunisation Skills Workshop – Friday 2 September 2022

MVEC are pleased to invite you to save the date for our Immunisation Skills Workshop taking place on Friday 2nd September. 

The full day interactive, face to face workshop is MVEC’s newest education opportunity designed to provide education and upskilling in the principles and processes of managing: 

  • effective vaccine communication 
  • error prevention and management 
  • anaphylaxis and acute stress responses 

Participants will hear from immunisation experts and have the opportunity to engage in simulated scenarios. 

The workshop will account for 12 nursing CPD hours and up to 24 points of CPD for pharmacist immunisers (including preparation and reading time). 

Further program details and a link to register will be available via our events page soon. 


NCIRS resource now available – Influenza vaccination coverage data

NCIRS have published a report outlining influenza vaccination coverage according to state/territory as well as age group, in Australia in 2022. Rates are compared to vaccination coverage reported in 2020 and 2021. This report will be updated weekly and uses data obtained from the Australian Immunisation Register.  

Influenza vaccines are recommended for all people aged ≥ 6 months. They are provided for free on the National Immunisation Program (NIP) for at-risk groups including children under 5, people with specific medical risk factors, pregnant women, people aged 65 and over and all Aboriginal and Torres Strait Islanders aged ≥ 6 months. Some individual jurisdictions are also providing free flu vaccination for all aged ≥ 6 months. Any other individuals who are unable to source a funded vaccine can obtain a flu vaccine for a small fee.  

As of the 11th June 2022, 31.6% of Australians aged 6 months and above had received an influenza vaccination, and just 20.2% of Aboriginal and Torres Strait Islander Peoples had received one.  

To view the NCIRS data, please click on the link below.
NCIRS Influenza vaccination coverage data 

For more information on influenza vaccines, please click on the link below. 
MVEC: Influenza recommendations


New resource for seniors added to the MVEC immunisation hub for the general public

Due to the immune system becoming less effective as we age and the increasing risk of severe disease, immunisation is an important aspect of health promotion for seniors.  

Our dedicated immunisation resource includes information for seniors on vaccine preventable diseases, vaccine recommendations, answers to frequently asked questions and links to further resources. 

MVEC’s hub of up-to-date and reliable information aims to increase the public’s awareness and understanding of vaccine preventable diseases and promote the benefits of immunisation for people of all ages. 

If you are interested in collaborating with MVEC to develop immunisation resources, we’d love to hear from you! 

To access this new resource for seniors, please click on the link below:  

Resource for seniors: MVEC’s new Immunisation hub for the general public

 


ATAGI recommendations on first booster dose in adolescents aged 12-15 years

ATAGI has provided updated advice regarding COVID-19 booster doses for those aged 12-15 years. 

A single booster dose of Comirnaty (Pfizer) is now recommended for the following select groups:  

  • those who are severely immunocompromised 
  • those who have a disability with significant or complex health needs 
  • those who have complex and/or multiple health conditions that increase the risk of severe COVID-19. 

Booster doses can be administered ≥ 3 months after the completion of the primary course, or ≥ 3 months after COVID-19 infection (whichever is later).  

There is currently insufficient evidence to support expanding this booster dose recommendation to other groups of adolescents aged 12-15 years, however this advice may change in the future as more evidence emerges.  

To read the advice in full please follow the link below.    

ATAGI recommendations on first booster dose in adolescents aged 12-15 years 


Updated MVEC immunisation reference page: Kawasaki disease and immunisation

MVEC’s reference page on Kawasaki disease and immunisation has recently been updated. This resource outlines:  

  • what Kawasaki disease is 
  • vaccine recommendations for providers 
  • specific precautions to take when vaccinating 

To view the page in full, follow the link below: 

MVEC: Kawasaki disease and immunisation 


ABC Radio Canberra with A/Prof Nigel Crawford: Influenza and the importance of the flu vaccine for children under five.

MVEC’s Associate Professor Nigel Crawford was interviewed by ABC Radio Canberra to discuss influenza in children under five. With younger children at greater risk of contracting severe disease, A/Prof Crawford explains the importance of vaccinating children every flu season to ensure the best protection. 

You can listen to the interview here:
ABC Radio Canberra: Influenza and the importance of the flu vaccine for children under five.


Save the date for our 2022 Clinical Vaccinology Update!

MVEC are pleased to announce that our next Clinical Vaccinology Update (CVU) will take place on Friday 28 October. The event will be held in-person at the University of Melbourne. 

The CVU will provide an opportunity for immunisation providers, industry partners and vaccine experts to come together for interactive professional development and networking. 

Program details and ticketing information will be announced shortly via our MVEC Events Page


Updated MVEC immunisation reference page: Meningococcal

MVEC’s meningococcal immunisation reference page has been updated. This resource details: 

  • meningococcal disease information, including symptoms and epidemiology 
  • recommendations for meningococcal ACWY vaccination 
  • recommendations for meningococcal B vaccination 

To view the page in full, follow the link below:

MVEC: Meningococcal 


Expanded ATAGI recommendations on winter COVID-19 booster doses for people at increased risk of severe COVID-19

ATAGI have updated their COVID-19 winter booster dose recommendations to include additional risk groups. The groups now eligible for winter booster doses include: 

  • Any adult aged 65 years and older  
  • Aged care or disability care residents aged 16 years and older  
  • Individuals aged 16 years and older with severe immunocompromise 
  • Aboriginal and Torres Strait Islander adults aged 50 years and older.  
  • Individuals from 16 years of age who have complex, chronic or severe conditions [refer to page 3 of ATAGI statement below] 

COVID-19 winter booster doses are not currently recommended for other groups including healthy people aged 16 to 64 years, healthy individuals with occupational risk factors (eg. healthcare workers) or pregnant women without additional risk factors.  

mRNA vaccines are the preferred option for booster doses with Comirnaty (Pfizer) available to give from 16 years of age and Spikevax (Moderna) from 18 years. In people aged 18 years or older with a contraindication to mRNA vaccines Vaxzevria (AstraZeneca) may be considered. Nuvaxovid (Novavax) can be used in individuals 18 years or older in circumstances where no other COVID-19 vaccine is suitable. 

To read the updated recommendations in full, please click on the link below:
Expanded ATAGI recommendations on winter COVID-19 booster doses for people at increased risk of severe COVID-19


New resource added to the MVEC immunisation hub for the general public

Adolescence is an important time to have vaccines due to an increased risk of exposure to some diseases as well as the decrease in previous immunity gained from childhood vaccines. 

Our dedicated immunisation resource for teenagers includes information on vaccine preventable diseases, vaccine recommendations, answers to frequently asked questions and links to further resources. 

MVEC’s hub of up-to-date and reliable information aims to increase the public’s awareness and understanding of vaccine preventable diseases and promote the benefits of immunisation for people of all ages. 

If you are interested in collaborating with MVEC to develop immunisation resources, we’d love to hear from you! 

To access the new MVEC immunisation hub, please click on the link below: 

MVEC’s Immunisation hub for the general public